DOCSLIB.ORG

List of Essential Drugs 1979 Eng

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Essential Drugs 1979 Eng SOUTH PACIFIC LIST OF ESSENTIAL DRUGS First Edition, 1979 Adopted by the WHO/SPEC MEETING ON TECHNICAL COOPERATION AMONG SOUTH PACIFIC COUNTRIES/AREAS IN PHARMACEUTICAL SUPPLIES Suva, Fiji q-8 Dece_ber 1978 Sponsored by the World Health Organization Regional Orfice for the Western Pacific and the South Pacific Bureau for Econo.ic Cooperation Not for Sale Printed and Distributed by the Regional Office for the Western Pacific of the World Health Organization Hanila, Philippines - i - NOTE BY THE SECRETARIAT At the WHO/SPEC meeting in Suva, 4-8 December 1978, it was agreed that the South Pacific List of Essential Drugs, as adopted, be published and disseminated. There was substantial discussion at the meeting, based on a combined list of drugs being used in five South Pacific countries, viz. Fiji, Papua New Guinea, Samoa, Solomon Islands and Tonga. The list adopted by the meeting - included a substantial number of the drugs of the WHO model list of essential drugs contained in WHO Technical Report Series No. 615; excluded the remainder of the drugs of the WHO model list of essential drugs, because the demand for them in the South Pacific countries/areas is either non-existent or insignificant; included a number of drugs not currently included in the WHO model list of essential drugs: these inclusions and the reasons for their inclusion are set out below; excluded a number of drugs not currently included in the WHO model list of essential drugs and which are being used in one or more of the South PaCific countries/areas, but which the meeting considered were not essential, not required or where the need for the drug can be more appropriately met by one of the drugs included in the South Pacific List of Essential Drugs. General reasons for inclusion of drugs which are not in the WHO model list of essential drugs are: A: current practice in one or more of the South Pacific countries/areas; B: less expensive than other drugs used for the same purpose. ANAESTHETICS General anaesth!tics ketamine hydrochloride: A ANALGESICS, ANTIPYRETICS, NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND ANTI GOUT DRUGS codeine compound tablets (BP): limited use, for cases where simple analgesics, e.g. acetylsalicylic acid and/or paracetamol, are ineffective phenylbutazone: A, B probenicid: A and also being included for adjunct treatment with penicillins (see Antibacterial drugs) - 11 - ANALGESICS, NARCOTICS AND NARCOTIC ANTAGONISTS nalorph1ne hydroohlor1de: A, B, to be superseded when the pr1ce of naloxone 1s substant1ally reduoed ANTIALLERGICS Ant1histamines promethazine hydr~ohlor1de: B, an alternative antihistamine ANTIDOTES, CHELATING AGENTS, ETC. deferoxamine mesilate: used in the treatment of acute iron poisoning Fuller's earth: treatment of paraquat pOisoning ipecaouanha: A, emetic ANTIEPILEPTICS paraldehyde: also used for non-epileptic oonvulsions sodium valproate: an ant1epilept1c which oan be efreotive in patients who do not raspond to other ant1ep11ept1c drugs ANTI INFECTIVE DRUGS Antibacter1al drugS amox1c1111n: an alternative to ampioillin clindamyc1n hydroohloride: A, used to treat osteomyelitis nitrofurantoin: A, B, treataent of ur1nary tract infections which do not respond to other therapy oxytetraoyoline hydroohloride: A, an alternative to tetraoyoline probeneoid: adjunct treatment with penioillins sulfa.ethlzo1el A, 8, an alternative drua for the treatmant of urinary traot infections Antiprotozoal druss !n!1!a!a!i~l~ dapsone with pyriaethamine: ourrently reoommended for prophylaxis of chloroquine-resistant malarias sulfadox1ne with pyrimethamine: currently reco.. ended for prophylaxis and treatment of chloroquine-resistant malarias - iii - Systemic antifungal drugs nystatin: A ANTINEOPLASTIC DRUGS calcium folinate: chlorambucil: A, drugs used in oncology mercaptopurine: BLOOD AND HAEHATOPOIETIC SYSTEM DRUGS Antianaemia drugs ferric ammonimum citrate: B, iron preparation for children Plasma substitutes polygeline (Haemaccel): useful for emergencies Plasma fractions for specific uses albumin, normal human serum: antihaemophilic concentrate (dried): fibrinogen (dried): A plasma protein, stable solution: P.P.S.B. (coagulation factors II, VII, IX, X, concentrate): CARDIOSVASCULAR DRUGS Antihypertensive drugs pentolinium tartrate: A sodium nitropruseide: A, an effective agent for hypertensive crisis Drugs used in shock metaraminol bitartrate: A DERMATOLOGICAL PREPARATIONS Topical Antiinfective benzoin compound tincture: A, inexpensive wound dressing cetrimonium bromide: A, for preparation of antiseptic cream, solution, etc. - iv - chlorhexidine gluconate: A, antiseptic cream chlorhexidine gluconate with cetrimide: A, antiseptic solution for topical use crystal violet: A, aqueous solution to treat skin infections hydrogen peroxide: A, mild disinfectant for topical use potassium permanganate: A, aqueous solution is a mild disinfectant silver sulfadiazine: A, cream is used to treat burns tetracycline hydrochloride: A, ointment is an alternative antibiotic topical preparation Antiinflammatory drugs ichthammol: A, used to treat chronic skin diseeses, including inflammatory conditions of ichthammol with glycerol: the external ear ichthammol ointment: Astringents calamine: A, mild skin astringent zinc oxide: A, mild skin astringent DIAGNOSTIC AGENTS Acetest: Albustix: Clinist1x: Clinitest: A, preparations for urine teeting Diastix: Labstix: Uristix: fluorescein sodium: A, for detection of corneal lesions or foreign bodies in the eye vasopressin tannate: A, renal function testing DIURETICS amiloride hydrochloride: potaaa1U11-sav1ng diuretic, alternative to tr1aJlterene oyclopenthiazide: alternat1ve thiazide diuretio to hydroohlorothiazide - v - EAR, NOSE, THROAT (ENT) spirit ear drops: A, B ephedrine hydrochloride nasal drops: A, B GASTROINTESTINAL DRUGS Antacids magnesium trisilloate compound mixture/tablets: A, alternative to magnesium hydroxide preparations Antiemetics metoclopramide: effective antiemetic; for restrioted use (expensive) proohlorperazine (maleate, meailate): alternative antiemetic to promethazine AntispasllOdica belladonna tincture: A, for incluaion in liquid oral preparations propantheline bromide: A, also uaeful for chronic neurogenic incontinence of Urine Cathartics bisacodyl: A glycerol suppository: A magnesium sulfate powder: A sodium dioatyl sulfoeuacinate with danthron: A Diarrhoea kaolin: kaolin and morphine mixture: A kaolln aixture for inrants: I - vi - HORHON&'> Adrenal hormones and eynthetic aubstitutes methylprednisolone acetate: A, for intra-articular injection prednisone: alternative to prednisolone Contraceptives ethynodiol diacetate with mestranol: an alternative progestogen­ estrogen combination medroxyprogesterone aoetate: long-acting injectible contracceptive norethisterone with mestranol: alternative progestogen-eatrogen combinations norgeatrel with ethinyleatradiol: Estrosens diethylatilbestrol: used for the treatment of prostatic carCinoma Inaul1na insulin zinc suspension (amorphoua): insulin zinc suspenaion (cryatalline): A isophane insulin: protamine zinc inaulin: Thyroid hormone. and antasonist. oarb1mazole: A, alternative to propylthiouracil HYPOOLYCAEHIC DRUGS, ORAL chlorpropamide: A, B metformin: A, limited use tolbutamide: A, B IHHUI«lLOGICALS Sera and immunoslcbulins immunoglobulin, human antitetanua: A, preferred over tetanua antitoxin atone fish ant1vellOll: 1 - vii - Vaccines cholera vaccine: yellow fever vaocine: • travel requirement of some governments MUSCLE RELAXANTS (PERIPHERALLY ACTING) AND ANTAGONISTS pancuronium bromide: A OPHTHALMOLOGICAL PREPARATIONS Topical Antl1nfective chloramphenicol: A oxytetracycline: alternative to tetracycline Antiinflammatory betamethasone sodium phosphete: A, alternatives to hydrooortisone prednisolone sodium phosphate: MioUoa physost1lmine: A MydrbUos atropine sulfate: A oyolopentolate hydroohloride: A phenylephrine hydroohloride: A PREPARATIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES Ilucose in 1/2-atrensth Darrow's solution: A potasaium ohloride tablet: A PSYCOOTIIERAPEUTIC DRUGS amobarbitel sodium: A chloral hydrate: A trifluoperazine hydroohloride: A, an alternative phenothiazine - viii - RESPIRATORY TRACT, DRUGS ACTING ON THE Antiasthmatio drugs beclometasone dlpropionate: non-systemio oorticosteroid prophylaxis of asthma attaoks cromoglicic acid: prophylaxis of asthma orciprenaline sulfate: an alternative to salbutamol theophylline with ephedrine hydrochloride and phenobarbital: A Antltuasives "cough mixture": A "cough mixture for infants": VITAHINS AND HINERALS vitamin B group with ascorbic acid injection: A, for use in malnutrition states MISCELLANEOUS DRUGS boric acid: to manufacture Eusol chlorinated lime: ood liver oil ointment: for treatment of burns dimeticone oream: for use by stoma tees emulSifying ointment: base for topical preparations formaldehyde solution: preserving agent lubricating jelly, surgical: A magnesium sulfate paste: A, topioal use methyl salicylate liniment: A, for muscular sprains monoethanolamine oleate injection: A, treatment of varicose veins oily cream (BP): base for topical preparations silver nitrate: for manufacture of silver sulfadiazine cream turpentine liniment: A, rubefacient for muscular conditions INTRODUCTORY REMARKS 1. ·The South Pacific List of Essential Drugs is based on the WHO model list of essential drugs contained in the WHO Technical Report Series No. 615, "The selection of essential drugs". In compiling the list, due consideration was given to local experience and practice. 2. A plus sign
Load more

Recommended publications
  • Surfen, a Small Molecule Antagonist of Heparan Sulfate
    Surfen, a small molecule antagonist of heparan sulfate Manuela Schuksz*†, Mark M. Fuster‡, Jillian R. Brown§, Brett E. Crawford§, David P. Ditto¶, Roger Lawrence*, Charles A. Glass§, Lianchun Wang*, Yitzhak Torʈ, and Jeffrey D. Esko*,** *Department of Cellular and Molecular Medicine, Glycobiology Research and Training Center, †Biomedical Sciences Graduate Program, ‡Department of Medicine, Division of Pulmonary and Critical Care Medicine and Veteran’s Administration San Diego Medical Center, ¶Moores Cancer Center, and ʈDepartment of Chemistry and Biochemistry, University of California at San Diego, La Jolla, CA 92093; and §Zacharon Pharmaceuticals, Inc, 505 Coast Blvd, South, La Jolla, CA 92037 Communicated by Carolyn R. Bertozzi, University of California, Berkeley, CA, June 18, 2008 (received for review May 26, 2007) In a search for small molecule antagonists of heparan sulfate, Surfen (bis-2-methyl-4-amino-quinolyl-6-carbamide) was first we examined the activity of bis-2-methyl-4-amino-quinolyl-6- described in 1938 as an excipient for the production of depot carbamide, also known as surfen. Fluorescence-based titrations insulin (16). Subsequent studies have shown that surfen can indicated that surfen bound to glycosaminoglycans, and the extent block C5a receptor binding (17) and lethal factor (LF) produced of binding increased according to charge density in the order by anthrax (18). It was also reported to have modest heparin- heparin > dermatan sulfate > heparan sulfate > chondroitin neutralizing effects in an oral feeding experiments in rats (19), sulfate. All charged groups in heparin (N-sulfates, O-sulfates, and but to our knowledge, no further studies involving heparin have carboxyl groups) contributed to binding, consistent with the idea been conducted, and its effects on HS are completely unknown.
    [Show full text]
  • Management of Cutaneous Hemangiomas in Pediatric Patients
    PEDIATRIC DERMATOLOGY Series Editor: Camila K. Janniger, MD Management of Cutaneous Hemangiomas in Pediatric Patients Maria Letizia Musumeci, MD, PhD; Karina Schlecht, MD, PhD; Rosario Perrotta, MD; Robert A. Schwartz, MD, MPH; Giuseppe Micali, MD Cutaneous hemangiomas (CHs) are common benign during the first year of life and slow involution that vascular tumors of childhood. Clinically, they are usually is completed by 5 to 10 years of age.1 For characterized by a typical evolution profile, consist- this reason, no treatment is necessary in most cases. ing of a rapid proliferation during the first year of However, when CHs are located in areas at risk for life and slow involution that usually is completed functional complications; are of considerable size; or by 5 to 10 years of age. In most cases, no treat- repeatedly undergo bleeding, ulceration, or superin- ment is necessary. However, when CHs are located fection, a prompt and adequate treatment approach in areas at risk for functional complications; are of is required.2 considerable size; or repeatedly undergo bleeding, ulceration, or superinfection, a prompt and adequate Epidemiology treatment approach is required. First-line approaches CHs are present in 1.0% to 2.6% of neonates and in include topical, intralesional, and systemic corti- 10% to 12% of infants by 12 months of age.3 Thirty costeroids. Second-line options include interferon percent of CHs are first evident at birth; the remain- alfa-2a and -2b, laser therapy, and surgical therapy. der appear during the second month of life. The Third-line approaches include cytotoxins, emboliza- frequency of these benign tumors increases in pre- tion, and angiogenesis inhibitors.
    [Show full text]
  • Pharmaceuticals and Medical Devices Safety Information No
    Pharmaceuticals and Medical Devices Safety Information No. 203 July 2004 Table of Contents 1. Serious skin disorders caused by pharmaceuticals ···················3 2. Effects of electromagnetic waves from antitheft devices, etc. on medical devices ······································7 3. Important Safety Information ··························································· 13 .1. Monoethanolamine Oleate ······························································· 13 .2. Clarithromycin ··················································································16 .3. Tegafur/Gimeracil/Oteracil Potassium ·············································· 22 .4. Melphalan (injectable dosage form) ················································· 25 4. Revision of PRECAUTIONS (No. 157) Milnacipran Hydrochloride (and 6 others) ···················································30 This Pharmaceuticals and Medical Devices Safety Information (PMDSI) is issued based on safety information collected by the Ministry of Health, Labour and Welfare. It is intended to facilitate safer use of pharmaceuticals and medical devices by healthcare providers. PMDSI is available on the Pharmaceuticals and Medical Devices Agency website (http://www.pmda.go.jp/english/index.html) and on the MHLW website (http://www.mhlw.go.jp/, Japanese only). Published by Translated by Pharmaceutical and Food Safety Bureau, Pharmaceuticals and Medical Devices Agency Ministry of Health, Labour and Welfare Pharmaceutical and Food Safety Bureau, Office of Safety, Ministry
    [Show full text]
  • PHARMACOLGY HOMEWORK Overdose Management Add In
    PHARMACOLGY HOMEWORK Overdose Management Add in important nursing notes for each of these medications and overdose management as well as administration route. Medication Overdose Nursing Notes (*Homework) Management (Routes) Acetaminophen Acetylcysteine Acetaminophen: (PO/PR) Route: PO, IV Max daily dose: 4000mg Acute toxicity (overdose) Monitor for S+S of hepatotoxicity (éLFTs, bilirubin, hypoglycemia, renal damage) Acetylcysteine: IV infusion: monitor for fluid overload and signs of hyponatremia such as changes in mental status Monitor for S+S of aspiration, bronchospasm, excess secretions Digitalis Digoxin Immune Fab Digoxin: (PO/IV) (Ovine, Digibind) Take apical pulse for 60sec. If < 60 BPM hold Route: IV digoxin dose and contact prescriber. Monitor serum digoxin (it has a narrow therapeutic index), potassium, magnesium, calcium. Monitor for S+S toxicity: anorexia, nausea, vomiting, diarrhea, visual disturbances, cardiac arrhythmias Digoxin Immune Fab: Skin allergy testing prior to administration for history of allergy or previous therapy of this drug Monitor cardiac status + rhythm, neurological status Toxicity reversal within an hour (adults), minutes (children) of antidote administration Monitor serum potassium, critical within first few hours; serum digoxin levels, ECG for 2-3 weeks post administration Heparin Protamine sulfate Heparin: (IV/SC) (IV) Monitor for spontaneous bleeding, thrombocytopenia Monitor aPTT levels Protamine Sulfate: Sudden drop in BP Monitor BP+ P q15-30 min Monitor aPTT Opioid Naloxone (IV-adults, Opioids:
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Antidote List
    Antidote List Recommended minimum amounts for hospital pharmacies to stock Call the Maryland Poison Center for expert advice on the treatment of all poisonings and overdoses: 1-800-222-1222 Poisoning Minimum Stocking Antidote Indication Recommendations Oral: 120 grams Acetylcysteine Acetaminophen IV: 96 grams Crotaline snake Antivenin, snake (CroFab®) 12 vials envenomation 1 vial Black widow spider (Note: Merck limits distribution Antivenin, black widow spider envenomation to cases of confirmed bites with symptoms only) Organophosphate & Atropine carbamate insecticides, nerve 165 mg gases Calcium chloride Calcium channel blockers 10 grams 2.25 grams Calcium disodium EDTA Lead (Available direct from ASD Specialty Healthcare) Hydrofluoric acid 1 kg (powder) Calcium gluconate Calcium channel blockers IV: 30 grams 1 kit Cyanide Antidote Kit Cyanide (or Hydroxocobalamin, see below) Cyproheptadine (Periactin®) Serotonin syndrome 80 mg Neuroleptic malignant Dantrolene syndrome, stimulant-induced 720 mg hyperthermia Deferoxamine mesylate Iron 8 grams (Desferal®) Digoxin Immune FAB Digoxin 20 vials (Digibind®, DigiFab®) Dimercaprol (BAL) Heavy metals 1.5 grams 1 | P a g e Maryland Poison Center Antidote List – continued Poisoning Minimum Stocking Antidote Indication Recommendations DMSA (Succimer, Chemet®) Heavy metals 2000 mg Folic acid Methanol IV: 150 mg Flumazenil (Romazicon®) Benzodiazepines 10 mg Fomepizole (Antizol®) Ethylene glycol, methanol 12 grams Beta blockers, Glucagon 50 mg calcium channel blockers Hydroxocobalamin (Cyanokit®) Cyanide
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Protamine Sulfate Enhances Lipid-Mediated Gene Transfer
    Gene Therapy (1997) 4, 961–968 1997 Stockton Press All rights reserved 0969-7128/97 $12.00 Protamine sulfate enhances lipid-mediated gene transfer FL Sorgi1,2, S Bhattacharya1 and L Huang1 1The Laboratory of Drug Targeting, Department of Pharmacology, The University of Pittsburgh School of Medicine, Pittsburgh, PA, USA A polycationic peptide, protamine sulfate, USP, has been USP as a condensation agent was found to be superior to shown to be able to condense plasmid DNA efficiently for poly-L-lysine as well as to various other types of protamine. delivery into several different types of cells in vitro by sev- These differences among various salt forms of protamine eral different types of cationic liposomes. The monovalent appear to be attributable to structural differences between cationic liposomal formulations (DC-Chol and lipofectin) the protamines and not due to differences in the net charge exhibited increased transfection activities comparable to of the molecule. The appearance of lysine residues within that seen with the multivalent cationic liposome formu- the protamine molecule correlate with a reduction in bind- lation, lipofectamine. This suggests that lipofectamine’s ing affinity to plasmid DNA, as well as an observed loss in superior in vitro activity arises from its ability to condense transfection-enhancing activity. This finding sheds light on DNA efficiently and that protamine’s primary role is that of the structural requirements of condensation agents for use a condensation agent, although it also possesses several in gene transfer protocols. Furthermore, protamine sulfate, amino acid sequences resembling that of a nuclear localiz- USP is an FDA-approved compound with a documented ation signal.
    [Show full text]
  • Reducing the Use of Reversal Agents in a Community Hospital
    4/21/2016 Objectives • Review the appropriate use of reversal agents Reducing the Use of Reversal Agents in a Community Hospital • Identify opportunities for reduction strategies of reversal agents Maria Paulina Duarte, PharmD PGY-1 Pharmacy Resident • Understand pharmacist’s role in impacting the Mercy Hospital, A Campus of use of reversal agents Plantation General Hospital Background Reversal Agents • Drug overdoses, whether accidental or intentional, • Naloxone constitute a significant source of increasing ▫ Reversal of opioids morbidity, mortality, and healthcare expenditure Examples: Morphine, hydromorphone, and fentanyl worldwide1,2 ▫ Side effects: Cardiac complications • Flumazenil • Hospitalized patients are susceptible to accidental ▫ Reversal of benzodiazepines drug overdoses, and immediate reversal may be 3 Examples: Lorazepam, clonazepam, and diazepam warranted to decrease harm ▫ Side effects: May result in seizures • Vitamin K • However, in some clinical settings, it has become ▫ Reversal of vitamin K antagonist common practice to use reversal agents and in some Example: Warfarin occasions the use of reversal agents might not be of ▫ Side effects: May cause warfarin resistance value for a drug overdose3,4 Reversal Agents Study’s Objective • Protamine ▫ Reversal of heparin Example: Unfractionated heparin and low molecular To assess the utilization of reversal agents weight heparin ▫ Side effects: cardiac and pulmonary complications and identify areas to potentially streamline their use • Prothrombin Complex Concentrate
    [Show full text]
  • World Health Organization Model List of Essential Medicines, 21St List, 2019
    World Health Organizatio n Model List of Essential Medicines 21st List 2019 World Health Organizatio n Model List of Essential Medicines 21st List 2019 WHO/MVP/EMP/IAU/2019.06 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
    [Show full text]